Subclassifying chronic fatigue syndrome through exercise testing

Medicine and Science in Sports and Exercise

Volumn 35, Issue 6, 2003, Pages 908-913

  VanNess, J Mark ^a   Snell, Christopher R ^a   Strayer, David R ^c   Dempsey IV, Line ^b   Stevens, Staci R ^b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b Workwell Foundation   (United States)

^c HEMISPHERX BIOPHARMA INC   (United States)

Author keywords

Cardiac response; Cardiopulmonary analysis; Differential diagnosis; Functional capacity; Functional impairment; Graded exercise; Physical impairment

Indexed keywords

AMPLIGEN; IMMUNOMODULATING AGENT;

ADULT; ARTICLE; BODY MASS; CARDIOPULMONARY HEMODYNAMICS; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EXERCISE TEST; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OXYGEN CONSUMPTION; RESPIRATORY QUOTIENT; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ADULT; EXERCISE TEST; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PHYSICAL FITNESS; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX;

EID: 0038454788     PISSN: 01959131     EISSN: None     Source Type: Journal    
DOI: 10.1249/01.MSS.0000069510.58763.E8     Document Type: Article

References (38)

1. AMERICAN COLLEGE OF SPORTS MEDICINE. ACSM's Guidelines for Exercise Testing and Prescription, 6th Edition. Philadelphia: Lippincott, Williams & Wilkins, 2000.
2. BORG, G. Borg's Perceived Exertion and Pain Scales. Champaign, IL: Human Kinetics, 1998.
3. BUCHWALD, D., T. PEARLMAN, P. KITH, and K. SCHMALING. Gender differences in patients with chronic fatigue syndrome. J. Gen. Intern. Med. 9:387-401, 1994.
4. DE BECKER, P., J. ROEYKENS, M. REYNDERS, N. MCGREGOR, and K. DE MEIRLEIR. Exercise capacity in chronic fatigue syndrome. Arch. Intern. Med. 160:3270-3277, 2000.
5. DEMITRACK, M. A. Neuroendocrine correlates of chronic fatigue syndrome: a brief review. J. Psychiatry Res. 31:69-82, 1977.
6. DEMITRACK, M. A., and L. J. CROFFORD. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann. N. Y. Acad. Sci. 840:684-697, 1998.
7. DWORKIN, H. J., C. LAWRIE-HOPPEN, P. BOHDIEWICZ, and A. M. LERNER. Abnormal left ventricular myocardial dynamics in 11 patients with chronic fatigue syndrome. Clin. Nucl. Med. 19:675-677, 1994.
8. EDWARDS, R., H. GIBSON, J. CLAGUE, and T. HELLIWELL. Muscle histopathology and physiology in chronic fatigue syndrome. Ciba Foundation Symposium 173:102-117, 1993.
9. ENGLEBIENNE, P., C. V. HERST, M. FREMONT, T. VERBINNEN, M. VERHAS, and K. DEMEIRLEIR. The 2-5A pathway and signal transduction: a possible link to immune dysregulation and fatigue. In: P. Englebienne and K. DeMeirleir (Eds.). Chronic Fatigue Syndrome: A Biological Approach. Boca Raton, FL: CRC Press, 2002, pp. 99-130.
10. EVENGARD, B., R. S. SCHACTERLE, and A. L. KOMAROFF. Chronic fatigue syndrome: new insights and old ignorance. J. Intern. Med. 246:455-469, 1999.
11. FARRAR, D., S. LOCKE, and F. G. KANTROWITZ. Chronic fatigue syndrome. 1: Etiology and pathogenesis. Behav. Med. 21:5-16, 1995.
12. FUKUDA, K., S. E. STRAUS, I. HICKIE, M. C. SHARPE, J. G. DOBBINS, and A. KOMAROFF. Chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann. Intern. Med. 121:953-959, 1994.
13. GOSHORN, R. K. Chronic fatigue syndrome: a review for clinicians. Semin. Neurol. 18:237-242, 1998.
14. GUNNAR, A. B., and L. COCCHIARELLA. Guide to the Evaluation of Permanent Impairment, 3rd Ed. Chicago: American Medical Association, 2000, pp. 27-28.
15. HAIR, J. F. Jr., R. E. ANDERSON, R. L. TATHAM, and W. C. BLACK. Multivariate Data Analysis with Readings, 3rd Ed. New York: Macmillan, 1992, pp. 146-148,
16. HOLMES, G. P., J. E. KAPLAN, and L. B. SCHONBERGER. Definition of the chronic fatigue syndrome. Ann. Intern. Med. 109:512-522, 1988.
17. INBAR, O., R. ELIN, A. ROTSEIN, and B. J. WHIPP. Physiological responses to incremental exercise in patients with chronic fatigue syndrome. Med. Sci. Sports Exerc. 33:1463-1470, 2001.
18. JASON, L. A., J, A. RICHMAN, A. W. RADEMAKER, et al. A community-based study of chronic fatigue syndrome. Arch. Intern. Med. 159:2129-2137, 1999.
19. JASON, L. A., R. R. TAYLOR, C. L. KENNEDY, et al. Chronic fatigue syndrome: sociodemographic subtypes in a community-based sample. Eval. Health Prof. 23:243-263, 2000.
20. KLIMAS, N. G., F. R. SALVATO, R. MORGAN, and M. A. FLETCHER. Immunologic abnormalities in chronic fatigue syndrome. J. Clin. Microbiol. 28:1403-1410, 1990.
21. LERNER, A. M., S. H. BEQAJ, R. G. DEETER, J. T. FITZGERALD. IGM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2 (UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome. In Vivo 16:153-160, 2002.
22. LERNER, A. M., C. LAWRIE-HOPPEN, and H. J. DWORKIN. Repetitively negative changing T waves at 24-h electrocardiographic monitors in patients with chronic fatigue syndrome: left ventricular dysfunction in a cohort. Chest 104:1417-1421, 1993.
23. LERNER, A. M., J. GOLDSTEIN, C. H. CHANG, et al. Cardiac involvement in patients with chronic fatigue syndrome as documented with Holter and biopsy data in Birmingham. Michigan. Infect. Dis. Clin. Pract. 6:327-333, 1997.
24. LLOYD, A. R., and H. PENDER. The economic impact of chronic fatigue syndrome. Med. J. Aust. 157:599-601, 1997.
25. MAKE, B., and J. F. JONES. Impairment of patients with chronic fatigue syndrome. J. Chronic Fatigue Syndr. 3:43-55, 1997.
26. MCCULLY, K. K., and B. H. NATELSON. Impaired oxygen delivery in chronic fatigue syndrome. Clin. Sci. 97:603-608, 1999.
27. MCCULLY, K. K., B. H. NATELSON, S. IOTTI, and J. S. LEIGH. Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle & Nerve 19:621-625, 1996.
28. PAGANI, M., D. LUCINI, G. S. MELA, W. LANGEWIT, and A. MALLIANI. Sympathetic overactivity in subjects complaining of unexplained fatigue. Clin. Sci. 87:655-661, 1994.
29. RILEY, M. S., C. J. O'BRIEN, D. R. MCCLOSKEY, N. P. BELL, and D. P. NICHOLLS. Aerobic work capacity in patients with chronic fatigue syndrome. Br. Med. J. 301:953-956, 1990.
30. SISTO, S. A., J. LAMANCA, D. L. CORDERO, et al. Metabolic and cardiovascular effects of a progressive exercise test in patients with chronic fatigue syndrome. Am. J. Med. 100:634-640, 1996.
31. SHEPHARD, R. J. Chronic fatigue syndrome, an update. Sports Med. 31:167-194, 2001.
32. STRAYER, D. R., W. A. CARTER, I. BRODSKY, et al. A controlled trial with a specifically configured RNA drug, Poly(I) • Poly(C12U), in chronic fatigue syndrome. Clin. Infect. Dis. 18(Suppl. 1):S88-S95, 2001.
33. THOMAS, J. R., and J. K. NELSON. Research Methods in Physical Activity, 3rd Ed. Champaign, IL: Human Kinetics, 1996, pp. 159.
34. VANNESS, J. M., C. R. SNELL, D. M. FREDRICKSON, D. R. STRAYER, and S. R. STEVENS. Assessment of functional impairment by cardiopulmonary exercise testing in patients with chronic fatigue syndrome. In: Innovations in Chronic Fatigue Syndrome Research and Clinical Practice, R. Patarca-Montero (Ed.). New York: Haworth Medical Press, 2001, pp. 103-110.
35. VOJDANI, A., P. C. CHOPPA, and C. W. LAPP. Downregulation of RNAse L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue syndrome. J. Clin. Lab. Immunol. 50:1-6. 1998.
36. WASSERMAN, K., J. E. HANSEN, D. Y. SUE, B. J. WHIPP, and R. CASABURI. Principles of Exercise Testing and Interpretation, 2nd Ed. Baltimore: Williams & Wilkins, 1994, pp. 113.
37. WEBSTER, B. H. Cardiac complication of infectious mononucleosis: a review of the literature and report of five cases. Am. J. Sci. 234:62-70, 1957.
38. WHITING, P., A. BAGNALL, A. SOWDEN, J. CORNELL, C. MULROW, and G. RAMIREZ. Interventions for the treatment and management of chronic fatigue syndrome. JAMA 286:1360-1368, 2001.